| 8.02 -0.15 (-1.84%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.57 | 1-year : | 13.31 |
| Resists | First : | 9.91 | Second : | 11.39 |
| Pivot price | 8.84  |
|||
| Supports | First : | 7.51 | Second : | 6.24 |
| MAs | MA(5) : | 8.1 |
MA(20) : | 9.16 |
| MA(100) : | 8.57  |
MA(250) : | 7.26 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 11.7 |
D(3) : | 8.4 |
| RSI | RSI(14): 36.7 |
|||
| 52-week | High : | 11.44 | Low : | 4.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ SGMT ] has closed above bottom band by 18.6%. Bollinger Bands are 38.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.28 - 8.32 | 8.32 - 8.36 |
| Low: | 7.81 - 7.87 | 7.87 - 7.93 |
| Close: | 7.93 - 8.02 | 8.02 - 8.1 |
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Fri, 16 Oct 2026
Sagimet Biosciences Inc. (SGMT) stock price, news, quote and history - Yahoo Finance UK
Thu, 15 Oct 2026
Sagimet Biosciences Inc. (SGMT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Thu, 15 Oct 2026
After Plunging 27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT) - Yahoo Finance
Thu, 15 Oct 2026
Sagimet Biosciences Inc. (SGMT) Options Chain - Yahoo! Finance Canada
Wed, 07 Oct 2026
Warrants carry a 9.99% ownership cap in a passive Sagimet Biosciences (SGMT) stake. - Stock Titan
Mon, 05 Oct 2026
Sagimet Biosciences (NasdaqGM:SGMT) Stock Forecast & Analyst Predictions - Simply Wall Street
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 70 (M) |
| Shares Float | 57 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 77.1 (%) |
| Shares Short | 11,190 (K) |
| Shares Short P.Month | 10,110 (K) |
| EPS | -1.27 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.15 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -16.5 % |
| Return on Equity (ttm) | -24.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -42 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | -6.32 |
| PEG Ratio | 0 |
| Price to Book value | 1.93 |
| Price to Sales | 0 |
| Price to Cash Flow | -13.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|